A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol1989;16:585–91.
Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol1994;10:1808–13.
American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum1996;39:713–22.
Felson DT, Anderson JJ, Meehan RF. Use of short‐term efficacy/toxicity trade‐offs to select second‐line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum1992;35:1117–25.
Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol1992;19:1885–94.
Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry1996;35:1270–3.
Ruckemann K, Fairbanks LD, Carrey EA et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen‐stimulated T lymphocytes from healthy humans. J Biol Chem1998;273:21682–91.
Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T‐lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem1995; 270:29682–9.
Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double‐blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet1999;353:259–66.
Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med1999;159:2542–50.
Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988;31:315–24.
Smolen JS, Breedveld FC, Eberl G et al. Validity and reliability of the twenty‐eight‐joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38–43.
Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum1995;38:727–35.
Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol1977;18:481–91.
Cash JM, Klippel JH. Second‐line drug therapy for rheumatoid arthritis. N Engl J Med1994;330:1368–75.
Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol1998;25:408–16.
Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum1992;35:729–35.
Weber W, Harnisch L. Use of a population approach to the development of leflunomide: A new disease‐modifying drug in the treatment of rheumatoid arthritis. In: Aarons L, Balant LP, Danhof M et al., eds. European cooperation in the field of scientific and technical research. Brussels: European Commission Directorate‐General Science, Research and Development, 1997:239–44.
Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double‐blind, placebo‐controlled trial. Ann Intern Med1994;121:833–41.
Ortiz Z, Shea B, Suarez‐Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol1998;1:36–43.
Van Ede A, Laan R, Rood M et al. Effect of folic and folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: A randomized, double‐blind, 48‐week clinical trial. Arthritis Rheum1999;42(Suppl.):S380.